Comparative Pharmacology
Head-to-head clinical analysis: NERLYNX versus ROZLYTREK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NERLYNX versus ROZLYTREK.
NERLYNX vs ROZLYTREK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neratinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor that inhibits EGFR, HER2, and HER4, leading to reduced downstream signaling and cell proliferation.
Entrectinib is a potent inhibitor of tropomyosin receptor tyrosine kinases (TRK) A, B, and C, and also inhibits ROS1 and ALK. It blocks downstream signaling pathways including MAPK, PI3K/AKT, and PLCγ, leading to apoptosis and reduced tumor growth in cancers with NTRK or ROS1 fusions.
NERLYNX (neratinib) 240 mg (6 tablets of 40 mg) orally once daily with food for a total duration of 1 year.
200 mg orally once daily with or without food.
None Documented
None Documented
Terminal half-life approximately 7–17 days (mean ~9 days) after a 240 mg daily dose, supporting once-daily dosing. Steady state reached by ~4–6 weeks.
Terminal half-life approximately 24 hours; supports once-daily dosing, steady-state reached in ~5 days.
Primarily hepatic metabolism; 97% of dose recovered in feces (including unchanged drug and metabolites), <1% in urine as unchanged drug. Biliary excretion is a major route.
Primarily hepatic metabolism via CYP3A4; 63% of dose recovered in feces (mostly as metabolites), 18% in urine (9% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor